Status:

COMPLETED

Network on Antimicrobial Resistance in Staphylococcus Aureus

Lead Sponsor:

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions:

Staphylococcus Aureus

Eligibility:

All Genders

Brief Summary

Reduced susceptibility of Staphyloccus aureus to the glycopeptide antibiotic vancomycin is causing increasing concern worldwide in view of the threat of increased morbidity and mortality caused by suc...

Detailed Description

Reduced susceptibility of Staphyloccus aureus to the glycopeptide antibiotic vancomycin is causing increasing concern worldwide in view of the threat of increased morbidity and mortality caused by suc...

Eligibility Criteria

Inclusion

  • INCLUSION AND EXCLUSION CRITERIA:
  • This study is concerned with the collection of data on the antimicrobial phenotypes of bacterial isolates and not the patient(s) from which they were isolated. Therefore, criteria for the inclusion or exclusion of patients does not apply.

Exclusion

    Key Trial Info

    Start Date :

    March 16 2000

    Trial Type :

    OBSERVATIONAL

    End Date :

    June 17 2008

    Estimated Enrollment :

    Patients enrolled

    Trial Details

    Trial ID

    NCT00341913

    Start Date

    March 16 2000

    End Date

    June 17 2008

    Last Update

    July 2 2017

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    MRL Pharmaceutical Services

    Herndon, Virginia, United States, 20171-4603